ADVERTISEMENT

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

British Journal of Clinical Pharmacology

British Journal of Clinical Pharmacology

Volume 50 Issue 2, Pages 161 - 165

Published Online: 24 Dec 2001

Journal compilation © 2010 The British Pharmacological Society



< Previous Abstract  |  Next Abstract >

Save Article to My Profile      Download Citation      Request Permissions

Abstract |  References  |  Full Text: HTML, PDF (Size: 66K)  | Related Articles | Citation Tracking

First trimester exposure to cefuroxime: a prospective cohort study
Matitiahu Berkovitch, 1 Idit Segal-Socher, 1 Revital Greenberg, 1 Mordechai Bulkowshtein, 1 Judy Arnon, 2 Paul Merlob 3 & Asher Or-Noy 2
  1 Clinical Pharmacology and Toxicology Unit, Assaf Harofeh Medical Center, Zerifin,   3 Department of Neonatology, Rabin Medical Center, Beil inson Campus, Petah Tikva, affiliated to Sackler Faculty of Medicine, Tel Aviv University and   2 Israeli Teratogen Information Service, Israeli Ministry of Health and Hebrew University, Hadassah Medical School, Jerusalem, Israel.
Correspondence: Matitiahu Berkovitch, MD, Division of Paediatrics, Assaf Harofeh Medical Center, Zerifin 70300, Israel, Tel.: 972–8-9779152; Fax: 972 89779138; E-mail: mberkovitch@asaf.health.gov.il
Copyright Blackwell Science, 2000
KEYWORDS
cefuroxime • pregnancy • teratogenicity

ABSTRACT

Aims There are no published studies on the safety of cefuroxime use during pregnancy. We therefore investigated prospectively the possible teratogenic effect of intrauterine exposure to cefuroxime.

Methods One hundred and six women who received cefuroxime during the first trimester of pregnancy were recruited from three teratogen information centres in Israel. Exposed women were paired for age, smoking habits and alcohol consumption with references being exposed to nonteratogenic antibiotics administered for the same indications.

Results Maternal history, birthweight, gestational age at delivery, rates of live births, spontaneous abortions and fetal distress were comparable among the two groups. Rates of major malformations in the cefuroxime group (3.2%) did not differ from references (2%) (P = 0.61, relative risk = 1.56, 95% confidence interval 0.27–9.15). There was a significantly higher rate of induced abortions among the cefuroxime exposed women as compared to the references (P = 0.04, relative risk = 3.33, 95% confidence interval 0.94–11.77).

Conclusions Our data may suggest that exposure to cefuroxime during the first trimester is probably not associated with an increased risk for malformations or spontaneous abortions; however, in light of the small sample size and the broad confidence limits, larger studies are needed to confirm these findings.


Received 22 October 1999, accepted 11 April 2000.

DIGITAL OBJECT IDENTIFIER (DOI)
10.1046/j.1365-2125.2000.00240.x About DOI

Related Articles

  • Find other articles like this in Wiley InterScience
  • Find articles in Wiley InterScience written by any of the authors

Wiley InterScience is a member of CrossRef.

Cross Ref Member


Sign Up Now
Sign Up Now